CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection FractionMichael McDonald, Amelia Yip, Sean Virani et al.|Canadian Journal of Cardiology|2021Cited by 290
Global Variations in Heart Failure Etiology, Management, and OutcomesYing Tung Sia, Eduardo Abib, S Bazan et al.|JAMA|2023Cited by 164
CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in AmyloidosisEileen O’Meara, Bruce Sussex, Michael McDonald et al.|Canadian Journal of Cardiology|2020Cited by 121
Effects of Combined Candesartan and ACE Inhibitors on BNP, Markers of Inflammation and Oxidative Stress, and Glucose Regulation in Patients With Symptomatic Heart FailureMichel White, Rhian M. Touyz, Serge Lepage et al.|Journal of Cardiac Failure|2007Cited by 47
Effects of AGTR1 A1166C Gene Polymorphism in Patients with Heart Failure Treated with CandesartanSimon de Denus, Michel White, Marcin Zakrzewski‐Jakubiak et al.|Annals of Pharmacotherapy|2008Cited by 41